Aliases & Classifications for Measles

Summaries for Measles

MedlinePlus : 40 Measles is an infectious disease caused by a virus. It spreads easily from person to person. It causes a blotchy red rash. The rash often starts on the head and moves down the body. Other symptoms include Fever Cough Runny nose Conjunctivitis (pink eye) Feeling achy and run down Tiny white spots inside the mouth Sometimes measles can lead to serious problems. There is no treatment for measles, but the measles-mumps-rubella (MMR) vaccine can prevent it. "German measles", also known as rubella, is a completely different illness. Centers for Disease Control and Prevention

MalaCards based summary : Measles, also known as rubeola, is related to mumps and encephalitis, and has symptoms including fever, cough and coryza. An important gene associated with Measles is CD46 (CD46 Molecule), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Vitamin A and BCG vaccine have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and skin, and related phenotypes are hematopoietic system and cellular

Disease Ontology : 12 A viral infectious disease that results_in infection located in skin, has material basis in Measles virus, which is transmitted_by contact with oronasal secretions, or semen of an infected person. The infection has symptom fever, has symptom cough, has symptom coryza, has symptom conjunctivitis, and has symptom maculopapular, erythematous rash.

CDC : 3 Measles starts with fever, runny nose, cough, red eyes, and sore throat. It’s followed by a rash that spreads over the body. Measles virus is highly contagious virus and spreads through the air through coughing and sneezing. Make sure you and your child are protected with measles, mumps, and rubella (MMR) vaccine.

Wikipedia : 72 Measles is a highly contagious infection caused by the measles virus. Initial signs and symptoms... more...

Related Diseases for Measles

Diseases related to Measles via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 272)
# Related Disease Score Top Affiliating Genes
1 mumps 30.9 CD40LG CD46 IFNAR2 IFNG IL2 STAT1
2 encephalitis 30.5 CD209 DDX58 TLR3
3 hepatitis 30.4 DDX58 EIF2AK2 IFNA1 IFNAR2
4 meningitis 30.1 CD40LG IFNG TLR2
5 stomatitis 30.0 ADAR DDX58 EIF2AK2 IFNA1
6 influenza 29.8 DDX58 EIF2AK2 IFNA1 IFNB1 IFNG TLR3
7 hepatitis b 29.7 IFNA1 IFNG STAT1 TLR2 TLR3
8 newcastle disease 29.7 DDX58 IFNA1 IFNB1
9 dengue virus 29.7 CD209 DDX58 IFIH1
10 tetanus 29.6 CD40LG IFNG IL2
11 mouth disease 29.5 IFNA1 IFNG STAT1
12 rheumatic disease 29.2 CD40LG IFNA1 IFNG
13 west nile virus 29.2 CD209 DDX58 IFIH1 IFNA1 TLR3
14 hepatitis c virus 29.2 ADAR DDX58 EIF2AK2 IFIH1 IFNG
15 multiple sclerosis 29.0 IFNA1 IFNB1 IFNG IL2 STAT1
16 cutaneous t cell lymphoma 28.9 IFNA1 IFNG IL2
17 vaccinia 28.7 EIF2AK2 IFNA1 IFNB1 IL2
18 herpes simplex 28.6 CD209 DDX58 EIF2AK2 IFIH1 IFNA1 IFNB1
19 hepatitis c 28.4 DDX58 EIF2AK2 IFNA1 IFNAR2 IFNB1 IFNG
20 human immunodeficiency virus type 1 28.0 ADAR CD209 IFNA1 IFNG IL2 STAT1
21 malaria 27.6 CD40LG FCGR2B IFNG IL2 TLR2
22 rubella 12.2
23 panencephalitis, subacute sclerosing 12.0
24 primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection 11.9
25 congenital rubella 11.3
26 acute disseminated encephalomyelitis 11.3
27 striatonigral degeneration, infantile 10.8
28 acute hemorrhagic leukoencephalitis 10.8
29 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 10.8
30 immunodeficiency 45 10.8
31 microcephaly 10.8
32 croup 10.8
33 immune-mediated encephalomyelitis 10.8
34 postinfectious encephalomyelitis 10.8
35 oral erosive lichen 10.5 IFNA1 IFNB1
36 marburg hemorrhagic fever 10.4 CD209 IFNB1
37 singleton-merten syndrome 10.4 DDX58 IFIH1
38 aging 10.3
39 human t-cell leukemia virus type 2 10.3 ADAR IFNG STAT1
40 neisseria meningitidis infection 10.3 CD46 MSN TLR2
41 fanconi anemia, complementation group c 10.3 EIF2AK2 IFNA1 STAT1
42 axillary adenitis 10.3 CD40LG STAT1
43 kyasanur forest disease 10.2 CD40LG IFNA1
44 microphthalmia with limb anomalies 10.2 IFNA1 IFNB1 STAT1
45 fasciolopsiasis 10.2 CD40LG IFNA1
46 aspergillosis 10.2 CD209 IFNG TLR2
47 relapsing-remitting multiple sclerosis 10.2 IFNA1 IFNB1 IFNG
48 extrinsic cardiomyopathy 10.2 CD40LG IFNB1 TLR3
49 la crosse encephalitis 10.2 CD40LG DDX58 IFNB1
50 diphtheria 10.2

Graphical network of the top 20 diseases related to Measles:



Diseases related to Measles

Symptoms & Phenotypes for Measles

Symptoms:

12
  • fever
  • cough
  • coryza
  • conjunctivitis
  • maculopapular

UMLS symptoms related to Measles:


koplik spots, pruritus, fever, exanthema

MGI Mouse Phenotypes related to Measles:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.24 SLAMF1 STAT1 TLR2 TLR3 IL2 FCGR2B
2 cellular MP:0005384 10.14 IL2 STAT1 TLR2 IFNG EIF2AK2 FCGR2B
3 homeostasis/metabolism MP:0005376 10.13 IL2 STAT1 TLR2 TLR3 FCGR2B ADAR
4 immune system MP:0005387 10.13 SLAMF1 STAT1 TLR2 TLR3 IL2 FCGR2B
5 mortality/aging MP:0010768 9.77 IL2 STAT1 TLR2 TLR3 IFNG EIF2AK2
6 liver/biliary system MP:0005370 9.76 IL2 STAT1 TLR2 FCGR2B ADAR IFIH1
7 neoplasm MP:0002006 9.28 STAT1 TLR2 TLR3 IL2 DDX58 IFNAR2

Drugs & Therapeutics for Measles

Drugs for Measles (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 106)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 68-26-8, 11103-57-4 445354
2
BCG vaccine Investigational Phase 4,Phase 2
3 Retinol palmitate Phase 4,Phase 3
4 Micronutrients Phase 4,Phase 3
5 Trace Elements Phase 4,Phase 3
6 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
7 Vitamins Phase 4,Phase 3
8 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
9 Protective Agents Phase 4,Phase 3
10 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
11 Antioxidants Phase 4,Phase 3
12 Adjuvants, Immunologic Phase 4
13 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2
14 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
15 Immunosuppressive Agents Phase 4,Phase 2,Phase 1
16 Liver Extracts Phase 4,Phase 1
17 retinol Nutraceutical Phase 4,Phase 3
18
Pyrimethamine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 58-14-0 4993
19
Sulfadoxine Approved, Investigational Phase 3,Phase 2,Phase 1 2447-57-6 17134
20
Mefloquine Approved, Investigational Phase 2, Phase 3 53230-10-7 4046
21
Iron Approved Phase 3 7439-89-6 23925
22
Tetracycline Approved, Vet_approved Phase 3,Phase 2 60-54-8 5353990
23
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613 2171
24
Sulfamethoxazole Approved Phase 3 723-46-6 5329
25
Dapsone Approved, Investigational Phase 2, Phase 3 80-08-0 2955
26
Proguanil Approved Phase 2, Phase 3 500-92-5 4923
27
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
28
Aluminum hydroxide Approved, Investigational Phase 3,Phase 2,Phase 1 21645-51-2
29
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
31
Lactitol Investigational Phase 3,Phase 2 585-86-4 3871
32
Chlorproguanil Investigational Phase 2, Phase 3 537-21-3 9571037 151170
33 Renal Agents Phase 3,Phase 2,Phase 1
34 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
35 Vitamin B Complex Phase 3,Phase 2,Phase 1
36 Anti-Infective Agents Phase 3,Phase 2,Phase 1
37 Antimalarials Phase 3,Phase 2,Phase 1
38 Fanasil, pyrimethamine drug combination Phase 3,Phase 2,Phase 1
39 Antiprotozoal Agents Phase 3,Phase 2,Phase 1
40 Antiparasitic Agents Phase 3,Phase 2,Phase 1
41 Rho(D) Immune Globulin Phase 3,Phase 2
42 gamma-Globulins Phase 3,Phase 2
43 Trimethoprim, Sulfamethoxazole Drug Combination Phase 3
44 Cytochrome P-450 Enzyme Inhibitors Phase 3
45 PENTA Phase 3,Phase 2
46 Anti-Bacterial Agents Phase 3,Phase 2
47 Immunoglobulins, Intravenous Phase 3,Phase 2
48 Antimetabolites Phase 2, Phase 3
49 Antibiotics, Antitubercular Phase 3,Phase 2
50 Antitubercular Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 233)

# Name Status NCT ID Phase Drugs
1 Additional Measles Vaccine at 4 Months of Age Unknown status NCT01486355 Phase 4
2 Trial of Additional Measles Vaccine to Reduce Child Mortality Unknown status NCT01644721 Phase 4
3 Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso. Unknown status NCT01668745 Phase 4
4 The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age Unknown status NCT01306006 Phase 4
5 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
6 Vitamin A Supplementation With Routine Childhood Vaccines and Mortality and Morbidity Unknown status NCT00168623 Phase 4 Vitamin A
7 Vitamin A Supplementation With Bacille Calmette Guerin (BCG) Vaccine Unknown status NCT00168610 Phase 4 Vitamin A
8 Coadministration of Measles-rubella and Rotavirus Vaccines Completed NCT01700621 Phase 4
9 Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines Completed NCT02643433 Phase 4
10 Early Two-dose Measles Vaccination Trial Completed NCT00168558 Phase 4
11 Long-term Follow-up of Measles Antibodies Completed NCT00168571 Phase 4
12 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine Completed NCT02880865 Phase 4
13 Non-Specific Effects of Standard Titre Measles Vaccination Completed NCT00168662 Phase 4
14 Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis Completed NCT00731965 Phase 4
15 Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00126997 Phase 4
16 Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine Completed NCT03160820 Phase 4
17 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Completed NCT01777529 Phase 4
18 Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Completed NCT00313950 Phase 4
19 Measles, Mumps, and Rubella (MMR) Immunity in College Students Completed NCT00962819 Phase 4
20 MMR Vaccination Among HIV-infected Adults Completed NCT02724852 Phase 4
21 Immunology of Non-specific Effects of Vaccine Completed NCT00168545 Phase 4
22 Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination Completed NCT00244673 Phase 4
23 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed NCT00326183 Phase 4
24 Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
25 Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067) Completed NCT00312858 Phase 4
26 IPV Clinical Trial - The Gambia Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
27 Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali Completed NCT02286895 Phase 4
28 Safety Study of a Refrigerator-stable Formulation of VARIVAX® Completed NCT00432731 Phase 4
29 Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children Completed NCT02253407 Phase 4
30 MMR and Varicella Vaccine in Premature Infants Completed NCT00156559 Phase 4
31 Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
32 Different Doses of Vitamin A Supplementation and Male and Female Morbidity and Mortality Completed NCT00168636 Phase 4 Vitamin A
33 Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV Completed NCT00329251 Phase 4
34 Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency Completed NCT00520494 Phase 4 Vivaglobin
35 Vitamin A With BCG Vaccine Completed NCT00168597 Phase 4 Vitamin A
36 Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine Recruiting NCT03330171 Phase 4
37 Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients Recruiting NCT01770119 Phase 4
38 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Recruiting NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
39 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines Recruiting NCT03368495 Phase 4
40 Homeopathic Vaccine Trial Recruiting NCT02825368 Phase 4
41 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR Active, not recruiting NCT02325310 Phase 4
42 The Phase IVd of Inactivated Enterovirus 71 Vaccine Enrolling by invitation NCT03296410 Phase 4
43 Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age Not yet recruiting NCT03071575 Phase 4
44 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination Not yet recruiting NCT03350698 Phase 4
45 Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines Terminated NCT00138255 Phase 4
46 Impact of the WHO Recommended Vitamin A Supplementation at Immunisation Contacts Terminated NCT00514891 Phase 4
47 Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants Unknown status NCT01763268 Phase 2, Phase 3
48 The Community Effectiveness of IPTi in Southern Tanzania Unknown status NCT00152204 Phase 3 Sulfadoxine-pyrimethamine used for IPTi;IPTi
49 Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Completed NCT02058563 Phase 3
50 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127010 Phase 3

Search NIH Clinical Center for Measles

Cochrane evidence based reviews: measles

Genetic Tests for Measles

Anatomical Context for Measles

The Foundational Model of Anatomy Ontology organs/tissues related to Measles:

18
Skin

MalaCards organs/tissues related to Measles:

38
Eye, Skin, Brain, T Cells, Testes, Lung, B Cells

Publications for Measles

Articles related to Measles:

(show top 50) (show all 1461)
# Title Authors Year
1
Measles-derived vaccines to prevent emerging viral diseases. ( 29410084 )
2018
2
Occurrence of measles in a country with elimination status: Amplifying measles infection in hospitalized children due to imported virus. ( 29447169 )
2018
3
Poor quality data challenges conclusion and decision making: timely analysis of measles confirmed and suspected cases line list in Southern Nations Nationalities and People's Region, Ethiopia. ( 29433436 )
2018
4
50 Years Ago in The Journal of Pediatrics: Atypical Exanthem after Exposure to Natural Measles: Eleven Cases in Children Previously Inoculated with Killed Vaccine. ( 29389454 )
2018
5
Assessment of Humoral Immunity to Hepatitis B, Measles, Rubella, and Mumps in Children After Chemotherapy. ( 29309372 )
2018
6
The role of extended and whole genome sequencing for tracking transmission of measles and rubella viruses: report from the Global Measles and Rubella Laboratory Network meeting, 2017. ( 29424220 )
2018
7
Absence of Measles Virus Detection from Stapes of Patients with Otosclerosis. ( 28971731 )
2018
8
Measles: what you can do. ( 29412035 )
2018
9
Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine. ( 29317117 )
2018
10
<i>In vitro</i> measles virus infection of human lymphocyte subsets demonstrates high susceptibility and permissiveness of both naive and memory B-cells. ( 29437964 )
2018
11
Measles and Rubella Global Strategic Plan 2012-2020 midterm review report: Background and summary. ( 29307368 )
2018
12
Measles and Rubella Global Strategic Plan 2012-2020 midterm review. ( 29307367 )
2018
13
Measles Virus Persistent Infection of Human Induced Pluripotent Stem Cells. ( 29412740 )
2018
14
Long-term Seroprotection Rates Following One-dose Measles (9-month) and One-dose MMR Vaccination (15 months) in Indian Children. ( 29428921 )
2018
15
Vaccination strategies and results for tackling the measles outbreak in CearA! State, Brazil, 2013-2015. ( 29412346 )
2018
16
2016 measles outbreak in Japan: A report of two cases with reappraisal of histological features. ( 29352499 )
2018
17
The neonatal anti-viral response fails to control measles virus spread in neurons despite interferon-gamma expression and a Th1-like cytokine profile. ( 29366594 )
2018
18
Seroprevalence of antibodies to measles and rubella eight months after a vaccination campaign in the southeast of Iran. ( 29420120 )
2018
19
Differential miRNA expression in B cells is associated with inter-individual differences in humoral immune response to measles vaccination. ( 29381765 )
2018
20
Polymorphisms in the Wilms Tumor Gene Are Associated With Interindividual Variations in Rubella Virus-Specific Cellular Immunity After Measles-Mumps-Rubella II Vaccination. ( 29253144 )
2018
21
Healthcare-associated Measles Following a Nationwide Outbreak in Mongolia. ( 29394341 )
2018
22
Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial. ( 29395526 )
2018
23
Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. ( 29426830 )
2018
24
Waning of measles maternal antibody in infants in measles elimination settings - A systematic literature review. ( 29398276 )
2018
25
The utility of measles and rubella IgM serology in an elimination setting, Ontario, Canada, 2009-2014. ( 28850604 )
2017
26
"Screening Different Host Cell Lines for the Dynamic Production of Measles Virus". ( 28054473 )
2017
27
A novel measles outbreak control strategy in the Netherlands in 2013-2014 using a national electronic immunization register: A study of early MMR uptake and its determinants. ( 28923422 )
2017
28
Timeliness of Measles Laboratory Reporting and Factors Associated with Delays, Zhejiang Province, China, 2009-2015. ( 28937792 )
2017
29
Soil transmitted helminth infections are not associated with compromised antibody responses to previously administered measles and tetanus vaccines among HIV-1 infected, ART naA^ve Kenyan adults. ( 28924616 )
2017
30
Comparison of cidofovir and the measles, mumps, and rubella vaccine in the treatment of recurrent respiratory papillomatosis. ( 28231366 )
2017
31
Measles burden in urban settings: characteristics of measles cases in Addis Ababa city administration, Ethiopia, 2004-2014. ( 28890752 )
2017
32
Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. ( 28558983 )
2017
33
Nonencapsidated 5' Copy-Back Defective Interfering Genomes Produced by Recombinant Measles Viruses Are Recognized by RIG-I and LGP2 but Not MDA5. ( 28768856 )
2017
34
Chickenpox and measles clusters among college students in Pune, Maharashtra. ( 29291222 )
2017
35
Pain caused by measles, mumps, and rubella vaccines: A systematic literature review. ( 28893478 )
2017
36
Micro-planning in a wide age range measles rubella (MR) campaign using mobile phone app, a case of Kenya, 2016. ( 29296151 )
2017
37
Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau. ( 28931238 )
2017
38
The Measles Virus Receptor SLAMF1 Can Mediate Particle Endocytosis. ( 28100610 )
2017
39
Ongoing outbreak with well over 4,000 measles cases in Italy from January to end August 2017 - what is making elimination so difficult? ( 28933342 )
2017
40
Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau. ( 28077730 )
2017
41
Transitioning Lessons Learned and Assets of the Global Polio Eradication Initiative to Global and Regional Measles and Rubella Elimination. ( 28838195 )
2017
42
Preliminary findings indicate nosocomial transmission and Roma population as most affected group in ongoing measles B3 genotype outbreak in Bulgaria, March to August 2017. ( 28920573 )
2017
43
The Conundrum in the Diagnosis and Management of Atypical Fulminant Measles in a Leukemia Survivor on Maintenance Chemotherapy. ( 27992394 )
2017
44
Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands. ( 28855159 )
2017
45
Mumps Virus Nucleoprotein and Hemagglutinin-Specific Antibody Response Following a Third Dose of Measles Mumps Rubella Vaccine. ( 29308410 )
2017
46
Mutations in the fusion protein of measles virus that confer resistance to the membrane fusion inhibitors carbobenzoxy-d-Phe-l-Phe-Gly and AS-48. ( 28904193 )
2017
47
Pivoting from polio eradication to measles and rubella elimination: a transition that makes sense both for children and immunization program improvement. ( 29296145 )
2017
48
A large population-based association study between HLA and KIR genotypes and measles vaccine antibody responses. ( 28158231 )
2017
49
Does Measles Vaccination Reduce the Risk of Acute Respiratory Infection (ARI) and Diarrhea in Children: A Multi-Country Study? ( 28076428 )
2017
50
Measles: A missed cause of acute tonsillitis. ( 29121387 )
2017

Variations for Measles

Expression for Measles

Search GEO for disease gene expression data for Measles.

Pathways for Measles

Pathways related to Measles according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 ADAR CD209 CD40LG CD46 DDX58 DHX58
2
Show member pathways
13.37 ADAR CD40LG DDX58 EIF2AK2 IFNA1 IFNAR2
3
Show member pathways
13 EIF2AK2 IFNA1 IFNAR2 IFNB1 IL2 STAT1
4
Show member pathways
12.98 CD209 IFNA1 IFNAR2 IFNB1 STAT1 TLR2
5
Show member pathways
12.82 CD40LG IFNA1 IFNG IL2 STAT1
6 12.81 IFNA1 IFNAR2 IFNG IL2 STAT1
7
Show member pathways
12.76 ADAR DDX58 DHX58 IFIH1 IFNA1 IFNB1
8
Show member pathways
12.68 CD40LG EIF2AK2 IL2 TLR2 TLR3
9
Show member pathways
12.57 ADAR DDX58 EIF2AK2 IFNA1 IFNAR2 IFNB1
10
Show member pathways
12.55 IFNA1 IFNAR2 IFNB1 IFNG IL2 STAT1
11
Show member pathways
12.52 IFNA1 IFNAR2 IFNB1 IFNG IL2
12
Show member pathways
12.39 IFNA1 IFNAR2 IFNB1 IFNG IL2 STAT1
13
Show member pathways
12.33 DDX58 EIF2AK2 IFIH1 IFNA1 IFNAR2 IFNB1
14
Show member pathways
12.31 IFNA1 IFNAR2 IFNB1 IFNG STAT1
15 12.29 CD209 FCGR2B IFNA1 IFNB1 IFNG STAT1
16
Show member pathways
12.24 ADAR CD209 CD46 DDX58 EIF2AK2 FCGR2B
17
Show member pathways
12.23 CD40LG IFNG STAT1 TLR2
18
Show member pathways
12.22 EIF2AK2 IFNA1 IFNAR2 IFNB1 IFNG STAT1
19 12.21 CD40LG CD46 DDX58 DHX58 IFIH1 IFNA1
20
Show member pathways
12.17 IFNB1 IFNG STAT1 TLR2
21 12.17 IFNG STAT1 TLR2 TLR3
22 12.1 FCGR2B IFNAR2 IFNB1 IFNG STAT1
23
Show member pathways
12.03 IL2 STAT1 TLR2 TLR3
24
Show member pathways
12.01 ADAR IFNA1 IFNAR2 IFNB1 IFNG IL2
25 11.99 CD209 IFNG IL2 SLAMF1
26 11.98 DDX58 EIF2AK2 IFNA1 IFNAR2 IFNB1 STAT1
27
Show member pathways
11.96 IFNG IL2 STAT1 TLR2 TLR3
28 11.9 IFNA1 IFNAR2 IFNB1 IFNG IL2 STAT1
29
Show member pathways
11.88 IFNG STAT1 TLR2 TLR3
30 11.79 CD209 IFNB1 IFNG IL2 SLAMF1
31 11.77 IFNG IL2 STAT1
32
Show member pathways
11.73 CD40LG IFNG IL2
33 11.72 CD40LG FCGR2B SLAMF1 TLR2
34 11.67 IFNAR2 IFNG IL2
35
Show member pathways
11.64 CD40LG IFNG IL2
36
Show member pathways
11.62 IFNAR2 IFNG IL2
37 11.51 CD40LG IFNG TLR2
38 11.44 EIF2AK2 IFNB1 IFNG STAT1
39 11.33 CD40LG IFNG IL2
40 11.28 IFNB1 IFNG IL2
41
Show member pathways
11.13 ADAR DDX58 EIF2AK2 IFNAR2 STAT1

GO Terms for Measles

Cellular components related to Measles according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 CD209 CD40LG IFNA1 IFNAR2 IFNB1 IFNG
2 cell surface GO:0009986 9.17 CD209 CD40LG CD46 MSN SLAMF1 TLR2

Biological processes related to Measles according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 9.99 CD209 CD46 IFNA1 IFNG IL2 SLAMF1
2 defense response GO:0006952 9.96 FCGR2B IFNA1 IFNB1 TLR3
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.96 CD40LG EIF2AK2 TLR2 TLR3
4 viral entry into host cell GO:0046718 9.9 CD209 CD46 NECTIN4 SLAMF1
5 immune system process GO:0002376 9.9 ADAR CD209 CD46 DDX58 DHX58 EIF2AK2
6 positive regulation of JNK cascade GO:0046330 9.87 FCGR2B SLAMF1 TLR3
7 B cell differentiation GO:0030183 9.86 CD40LG IFNA1 IFNB1
8 positive regulation of inflammatory response GO:0050729 9.86 IL2 TLR2 TLR3
9 positive regulation of T cell proliferation GO:0042102 9.86 CD209 CD40LG CD46 IL2
10 humoral immune response GO:0006959 9.85 IFNA1 IFNB1 IFNG
11 interleukin-12-mediated signaling pathway GO:0035722 9.85 IFNG MSN STAT1
12 positive regulation of interleukin-6 production GO:0032755 9.85 DDX58 TLR2 TLR3
13 negative regulation of viral genome replication GO:0045071 9.83 ADAR EIF2AK2 IFNB1
14 response to exogenous dsRNA GO:0043330 9.83 DDX58 IFNA1 IFNB1 TLR3
15 negative regulation of type I interferon production GO:0032480 9.82 DDX58 DHX58 IFIH1
16 B cell proliferation GO:0042100 9.81 CD40LG IFNA1 IFNB1
17 leukocyte cell-cell adhesion GO:0007159 9.81 CD209 CD40LG MSN
18 positive regulation of interleukin-8 production GO:0032757 9.8 DDX58 TLR2 TLR3
19 type I interferon signaling pathway GO:0060337 9.8 ADAR IFNA1 IFNAR2 IFNB1 STAT1
20 positive regulation of interleukin-10 production GO:0032733 9.78 CD40LG CD46 TLR2
21 regulation of type I interferon-mediated signaling pathway GO:0060338 9.78 IFNA1 IFNAR2 IFNB1 STAT1
22 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.77 IFNA1 IFNB1 IFNG
23 positive regulation of chemokine production GO:0032722 9.76 EIF2AK2 TLR2 TLR3
24 positive regulation of interferon-beta production GO:0032728 9.76 DDX58 IFIH1 TLR2 TLR3
25 cellular response to interferon-beta GO:0035458 9.74 IFNB1 STAT1 TLR3
26 positive regulation of interleukin-12 production GO:0032735 9.73 CD40LG IFNG TLR2 TLR3
27 regulation of innate immune response GO:0045088 9.72 DHX58 FCGR2B
28 positive regulation of interferon-alpha production GO:0032727 9.72 DDX58 IFIH1 STAT1
29 microglial cell activation GO:0001774 9.71 TLR2 TLR3
30 regulation of regulatory T cell differentiation GO:0045589 9.71 IFNG IL2
31 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.71 STAT1 TLR2
32 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.71 IFNG STAT1
33 I-kappaB phosphorylation GO:0007252 9.71 TLR2 TLR3
34 response to interferon-alpha GO:0035455 9.71 ADAR EIF2AK2 IFNAR2
35 negative regulation of phagocytosis GO:0050765 9.7 FCGR2B TLR2
36 positive regulation of regulatory T cell differentiation GO:0045591 9.7 CD46 IL2
37 positive regulation of tumor necrosis factor secretion GO:1904469 9.69 DDX58 IFIH1
38 response to interferon-beta GO:0035456 9.69 IFNAR2 STAT1
39 positive regulation of interferon-alpha secretion GO:1902741 9.68 DDX58 IFIH1
40 positive regulation of response to cytokine stimulus GO:0060760 9.67 DDX58 IFIH1
41 positive regulation of interferon-beta secretion GO:0035549 9.67 DDX58 IFIH1
42 detection of virus GO:0009597 9.67 DDX58 IFIH1 TLR3
43 cellular response to exogenous dsRNA GO:0071360 9.67 DDX58 IFIH1 IFNB1 TLR3
44 positive regulation of toll-like receptor signaling pathway GO:0034123 9.65 TLR2 TLR3
45 interleukin-10 production GO:0032613 9.64 CD46 TLR2
46 regulation of type III interferon production GO:0034344 9.62 DDX58 IFIH1
47 cytoplasmic pattern recognition receptor signaling pathway in response to virus GO:0039528 9.61 DDX58 IFIH1
48 response to virus GO:0009615 9.61 ADAR DDX58 DHX58 EIF2AK2 IFIH1 IFNAR2
49 defense response to virus GO:0051607 9.36 ADAR DDX58 DHX58 EIF2AK2 IFIH1 IFNA1
50 immune response GO:0006955 10.1 CD40LG FCGR2B IFNG IL2 TLR2

Molecular functions related to Measles according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.95 DDX58 EIF2AK2 IFIH1 NECTIN4 SLAMF1 STAT1
2 receptor activity GO:0004872 9.65 CD46 NECTIN4 SLAMF1 TLR2 TLR3
3 cytokine activity GO:0005125 9.55 CD40LG IFNA1 IFNB1 IFNG IL2
4 single-stranded RNA binding GO:0003727 9.54 DDX58 DHX58 IFIH1
5 virus receptor activity GO:0001618 9.26 CD209 CD46 NECTIN4 SLAMF1
6 double-stranded RNA binding GO:0003725 9.1 DDX58 DHX58 EIF2AK2 IFIH1 MSN TLR3
7 protein binding GO:0005515 10.28 ADAR CD209 CD40LG CD46 DDX58 DHX58

Sources for Measles

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....